BMY Bristol-Myers Squibb Company
Company Analysis
Latest News
🟢 Bristol-Myers Squibb is trading 4.1% up on October 20 amid healthcare-sector strength
Bristol-Myers Squibb is trading at $61.23, up 4.09%, with the gain appearing consistent with healthcare-sector strength, not a confirmed company-specific...
🟢 Bristol-Myers Squibb is trading 4.18% up today amid broader healthcare-sector strength
Bristol-Myers Squibb is trading at $61.76, up 4.18%, in line with strength across healthcare. - The supplied sector context reports XLV up 2.12%, supported by...
🟢 Bristol-Myers Squibb is trading 4% up today as healthcare stocks rally on UnitedHealth outlook
Bristol-Myers Squibb is trading at $58.94, up 4.01%, on October 14 as healthcare stocks rally after UnitedHealth beat quarterly earnings expectations and...
Bristol Myers Squibb Reports Admilparant Win at 60 mg for Lung Scarring
Bristol Myers Squibb announced positive topline results from its pivotal Phase 3 trial of experimental drug admilparant in patients with idiopathic pulmonary...
Bristol Myers Squibb Reports RYZ101 Improves Progression-Free Survival in Phase 3 Trial
Bristol Myers Squibb announced positive topline results from ACTION-1, a Phase 3 study of its radiopharmaceutical therapy RYZ101. The trial evaluated the drug...
🟢 Bristol-Myers Squibb is trading 6% up in pre-market
Bristol-Myers Squibb is trading 6.17% higher at $62.77, with no verified company-specific catalyst identified for the October 12 pre-market rise. - Coverage...
🟢 Bristol-Myers Squibb is trading 10.7% up in after-hours trading
Bristol-Myers Squibb is trading at $65.11, up +10.73% in after-hours trading, but available reports do not confirm the move or identify a verified...
🔴 Bristol-Myers Squibb is trading 4.17% down today after Leerink cuts rating and target to $59
Bristol-Myers Squibb is trading 4.17% down at $58.60 after Leerink Partners downgraded it from Outperform to Market Perform and cut its price target from $73...
Bristol Myers Squibb Tightens Liver Monitoring After Trial Death
Bristol Myers Squibb's experimental drug admilparant, being studied for idiopathic and progressive pulmonary fibrosis, faces heightened liver-safety scrutiny....
Bristol Myers Squibb deploys AI workbench, preventing clinical trial delays
Bristol Myers Squibb is integrating artificial intelligence across its research and development pipeline to accelerate medicine delivery. SVP for R&D Matteo...
Bristol Myers Squibb and Merck Gain FDA Label Update for PAH Drug Winrevair
The U.S. Food and Drug Administration (FDA) approved a label update for Winrevair. Bristol Myers Squibb and Merck jointly market Winrevair, a treatment for...
Bristol Myers Squibb Scraps $180M Cancer Asset, Overshadowing Sotyktu Success
Bristol Myers Squibb discontinued the development of ORM-6151, an experimental treatment for acute myeloid leukemia and myelodysplastic syndrome. Management...
Bristol Myers Squibb Sues Amgen Over Opdivo, Defending Key Revenue
Bristol Myers Squibb and Ono Pharmaceutical filed a patent infringement lawsuit against Amgen in Delaware federal court. The suit aims to prevent Amgen from...
Bristol Myers Squibb and Partner SystImmune Present Positive Lung Cancer Drug Data at WCLC
Bristol Myers Squibb and SystImmune announced new data from a global Phase 1 study. The study evaluated iza-bren (izalontamab brengitecan), a potential...
Bristol Myers Squibb's CAR T-Cell Therapy Succeeds in Multiple Myeloma Trial
Bristol Myers Squibb announced Tuesday that its experimental CAR T-cell therapy, arlocabtagene autoleucel (arlo-cel), achieved its primary goals in a Phase 2...
Bristol-Myers Squibb faces potential carnage, as milvexian trial becomes critical
H.C. Wainwright analysts highlighted intense pressure on Bristol-Myers Squibb regarding its upcoming milvexian clinical trial. This oral FXIa inhibitor trial...
Bristol Myers Pauses Zola-cel Trials, Reviews Inflammatory Safety Data
Bristol Myers Squibb voluntarily paused enrollment for its experimental CAR-T therapy, zolacabtagene autoleucel (zola-cel). The therapy targets autoimmune...
Bristol Myers Squibb to Invest Over $173 Million in Indiana Radiopharmaceutical Facility Through Subsidiary RayzeBio
Bristol Myers Squibb, via its subsidiary RayzeBio, will invest over $173 million. This expands operations in central Indiana. The project includes a new...
Bristol Myers Squibb Terminates CAR-T Manufacturing Pact with Cellares
Bristol Myers Squibb (BMY) terminated a partnership with cell therapy manufacturer Cellares. The canceled deal was potentially worth $380 million. The...
Renaissance Technologies Exits Bristol-Myers Squibb Stake
Jim Simons' quantitative hedge fund, Renaissance Technologies, has liquidated its entire position in Bristol-Myers Squibb (BMY), according to a recent...